Home Healthcare IT Dry Eye Syndrome Market Size, Share and Forecast to 2031

Dry Eye Syndrome Market

Dry Eye Syndrome Market Size, Share & Trends Analysis Report By Type (Evaporative Dry eye syndrome, Aqueous Dry eye syndrome), By Treatment Type: (Nutritional Supplements, Serum Eye Drops, Lubricant Eye Drops, Anti-inflammatory drugs Segments) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI74DR
Study Period 2020-2032 CAGR 5.2%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD XX Billion
Forecast Year 2032 Forecast Year Market Size USD XX Billion
Largest Market North America Fastest Growing Market Europe

Market Overview

The global dry eye syndrome market size was valued at around USD 2,200 million in 2017 and is expected to register CAGR of 5.2% in the forecast period.

Increasing frequency of dry eye syndrome among the population and growing number of life style disease are some of the factors driving the global dry eye syndrome market. LASIK is becoming highly normal now days and individuals undergoing LASIK surgery will suffer from the dry eye syndrome within the first six months of their treatment. Therefore, it is considered as one of the major driving factors for the growth of the market. Moreover, some of the other factors fueling the growth of the market includes rising the number of research and development and government initiatives. Additionally, another important factor boosting the growth of the market is the launch of new product in the market. Candorvision introduced the CALMO eye spray, which is one of the first eye spray free of preservatives in Canada.

Regional Analysis

Based on the geography, the market is split into four regions such as North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).

North America is expected to dominate the global market owing to increasing prevalence of dry eye syndrome in the U. S.  Furthermore, development of dry eye syndrome drugs and increasing number of approvals for new drugs and devices in the U.S. is driving the growth of the market. According to the American Journal of ophthalmology, around 6.8% of the U.S. adult population was projected to have diagnosed dry eye syndrome disease. Prevalence raised with the age of 18-34 years that is 2.7% and was higher in women (8.8%) then in men (4.5%).

Europe is expected to be second dominating region owing to increasing technological developments, government support, and various reimbursement policies.  However, adoption of contact lens is supporting the growth of the market. Furthermore, growing environmental pollution leading to allergy and dry eyes. Increasing incidences of vitamin A deficiency causing different eye diseases is supporting the growth of the market.

Asia Pacific is expected to grow at the significant rate due to the increasing number of patients with dry eye disease. Moreover, there is growing per capita healthcare expenditure and rising investment of key players in this market are some of the other factors boosting the market in APAC. In India increasing the prevalence of dry eye syndrome in women owing to hormonal changes during pregnancy and after menopause is propelling growth of the market.

LAMEA is exhibiting steady growth for the market due to less advanced technology. On the other hand, the Middle East & Africa holds the least share in the market due to the poor healthcare infrastructure, limited availability of funds, low spending power in Africa region. However, the region is expecting a sound growth due to many untapped opportunities in this region.

Report Scope

Report Metric Details
Segmentations
By Type
  1. Evaporative Dry eye syndrome
  2. Aqueous Dry eye syndrome
By Treatment Type:
  1. Nutritional Supplements
  2. Serum Eye Drops
  3. Lubricant Eye Drops
  4. Anti-inflammatory drugs Segments
Company Profiles Allergan Alcon Santen Pharmaceutical Co. Ltd. Shire/SAR code Bioscience Otsuka Holdings Can-Fite Biopharma Novartis Eyegate Pharma.
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global market of dry eye syndrome is segmented by type and treatment type.

On the basis of type the market is segmented into evaporative dry eye syndrome and aqueous dry eye syndrome. Evaporative eye syndrome is expected to lead dry eye syndrome market. Evaporative eye syndrome is an uncomfortable condition caused by a lack of quality tears.

Based on the treatment type, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, and anti-inflammatory drugs.

Market Size By Type

Recent Developments

  • In May 2018, Teva Canada Limited launched Teva-Cyclosporine ophthalmic emulsion. First generic version of Restasis (cyclosporine) in Canada.
  • In April 2018, Allergan launched TrueTear. Temporarily rise tear production during neurostimulation in adult dry eye syndrome patients.
  • In November 2017, Santen Pharmaceutical Co. Ltd. received the import drug license for Diquas Ophthalmic Solution for the treatment of dry eye syndrome in China.

Top Key Players

Dry Eye Syndrome Market Share of Key Players

Allergan Alcon Santen Pharmaceutical Co. Ltd. Shire/SAR code Bioscience Otsuka Holdings Can-Fite Biopharma Novartis Eyegate Pharma.

Frequently Asked Questions (FAQs)

What is the current size of the global dry eye syndrome market, and how is it expected to grow in the forecast period?
The global dry eye syndrome market was valued at USD 2,200 million in 2017, with a projected CAGR of 5.2% from 2023 to 2031.
Factors driving market growth include the increasing frequency of dry eye syndrome, the rise in lifestyle diseases, the prevalence of dry eye post-LASIK surgery, government initiatives, research and development activities, and the introduction of new products like Candorvision's CALMO eye spray.
Europe is identified as the fastest-growing market, driven by technological developments, government support, and reimbursement policies.
North America dominates the market due to the high prevalence of dry eye syndrome in the U.S., ongoing developments in dry eye syndrome drugs, and increasing approvals for new drugs and devices.
The market is segmented by type into evaporative dry eye syndrome and aqueous dry eye syndrome. Treatment segments include nutritional supplements, serum eye drops, lubricant eye drops, and anti-inflammatory drugs.
Key players in the market include Allergan, Alcon, Santen Pharmaceutical Co. Ltd., Shire/SAR code Bioscience, Otsuka Holdings, Can-Fite Biopharma, Novartis, and Eyegate Pharma.
The market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Factors contributing to growth vary by region, such as prevalence rates, technological advancements, government support, and environmental factors.


We are featured on :